|
RECTAL
Treatment with Two Chemotherapy Drugs Combined with Radiation Therapy for Patients with Rectal Cancer (NSABP R-04):
- Diagnosis of invasive rectal cancer
- Biopsy only of the tumor, no resection
- Tumor must be palpable by rectal exam
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with State II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (ECOG E5202):
- No history of isolated, distant, or non-contiguous intra-abdominal metastases, even if restricted
- Histologically confirmed adenocarcinoma of the colon
- Patients must have > 8 lymph nodes evaluated and reported
- Must not have presented with complete obstruction or perforation of the bowel
- Patients must not have had any systemic or radiation therapy initiated for this malignancy
A Randomized Phase III Trial of Oxaliplatin(OXAL) plus 5-FU/Leucovorin (CF) with or without Cetuximab after Curative Resection for Patients with Stage III Colon Cancer (NCCTG N0147):
- Tumor must have been completely resected
- At least 1+ lymph node w/no evidence of residual involved lymph node disease
- No prior radiation or chemotherapy for treatment of this malignancy
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum (CALGB 80405).
- Pathologically diagnosed advanced or metastatic colorectal cancer
- Patient can not of had prior chemotherapy for metastatic cancer
- No prior treatment with Bevacizumab and Avastin
|
